SHPH Nasdaq

Shuttle Pharmaceuticals Holdings, Inc.

SHPH | $0.4099 -2.69% 11K

(0.0% 1d) (-5.9% 1m) (-69.2% 1y) (0.0% 2d) (-2.4% 3d) (0.2% 7d) (17.57% volume)
Earnings Calendar:
Market Cap: $ 6,884,227

Sec Filling | Patents | 2022 employees

add to watch list Paper trade email alert is off

Press-releases

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
Published: 2024-04-03 (Crawled : 13:00) - globenewswire.com
SHPH | $0.4099 -2.69% 11K

| -6.39% | O: -8.31% H: 9.31% C: 6.45%
conference pharmaceuticals growth

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
Published: 2024-03-22 (Crawled : 13:00) - prnewswire.com
SHPH | $0.4099 -2.69% 11K

| -9.29% | O: -0.44% H: 2.0% C: -0.44%
pharma update

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Published: 2024-03-05 (Crawled : 14:00) - globenewswire.com
SHPH | $0.4099 -2.69% 11K

| 2.5% | O: -2.5% H: 2.56% C: 0.23%
conference pharmaceuticals growth

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
SHPH | $0.4099 -2.69% 11K

| 15.33% | O: 4.08% H: 0.0% C: -2.27%
pharma offering

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
SHPH | $0.4099 -2.69% 11K

| -28.88% | O: 4.42% H: 0.0% C: -16.11%
fda approval treatment pharmaceuticals trial glioblastoma

RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
Published: 2023-12-21 (Crawled : 11:00) - globenewswire.com
SHPH | $0.4099 -2.69% 11K

| -10.4% | O: -1.66% H: 8.89% C: 6.64%
medical

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
Published: 2023-12-11 (Crawled : 15:30) - biospace.com/
SHPH | $0.4099 -2.69% 11K

| -17.98% | O: 2.02% H: 0.59% C: -1.96%
fda pharmaceuticals application trial glioblastoma

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
SHPH | $0.4099 -2.69% 11K

| -15.57% | O: -0.1% H: 3.07% C: 3.05%
conference pharmaceuticals growth

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
Published: 2023-11-14 (Crawled : 15:30) - biospace.com/
SHPH | $0.4099 -2.69% 11K